Rhythm Pharmaceuticals (RYTM) Receivables (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Receivables data on file, last reported at $34.2 million in Q1 2026.

• Receivables for Q1 2026 came in at $34.2 million, up 91.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.2 million (up 91.82% YoY), and the FY2025 annual result was $26.1 million, up 40.89% from the prior year.
• Receivables climbed to $34.2 million in Q1 2026 per RYTM's latest filing, from $26.1 million in the prior quarter.
• Over five years, Receivables peaked at $34.2 million in Q1 2026 and troughed at $72.0 in Q1 2024.
• A 5-year average of $13.8 million and a median of $14.9 million in 2023 frame the typical range for Receivables.
• On a YoY basis, Receivables climbed as much as 26446475.34% in 2024 and fell as far as 100.0% in 2024.
• A 5-year view of Receivables shows it stood at $80.0 in 2022, then surged by 18583650.0% to $14.9 million in 2023, then rose by 24.52% to $18.5 million in 2024, then soared by 40.89% to $26.1 million in 2025, then soared by 31.1% to $34.2 million in 2026.
• Business Quant data shows RYTM's Receivables at $34.2 million in Q1 2026, $26.1 million in Q4 2025, and $33.0 million in Q3 2025.